Ensilication is a technology we developed that can physically stabilise proteins in silica without use of a pre-formed particle matrix 1 . Stabilisation is done by tailor fitting individual proteins with a silica coat using a modified sol-gel process 2 . 
Fluctuations in temperature, heating/freezing 3 , can affect biopharmaceuticals resulting in aggregation, protein unfolding leading towards loss of potency. Our previous research describes a new alternative to stabilise biopharmaceuticals at ambient temperatures using solgel technology 1 . Sol-gel is based upon the polymerisation of a monomeric species that can undergo condensation with another monomer of its species 2 . This eventually forms a particle as product which, in contact with other particles forms gels. There are many compounds that are compatible with this system, however our method uses a silica precursor, tetraethyl orthosilicate (TEOS). Hydrolysis of TEOS results in orthosilicic acid 15, 16 . This is a central Si atom bound with four hydroxyl (OH-) groups in a tetrahedral conformation and allows for rapid polymerisation under optimised conditions. The benefit here is the negative charge of silicic acid which we employ via electrostatics to direct it towards the positively charged biologically active component. Therefore, we can coat silica around a biologically active compound. The protein loaded silica powder obtained is resilient against fluctuations in temperature. TTCF is a ~52 kilodalton (kDa) fragment of the full tetanus neurotoxin and is a potent immunogenic protein. The DTP vaccine, which includes TTCF, has been shown to be susceptible to problems within cold chain transportation. This is represented by 16% lower vaccination coverage for DTP 8 in countries with poor infrastructure and results in higher prevalence of disease. Using TTCF as a model we demonstrate that ensilication could be an ideal solution to overcome the challenges of biopharmaceutical 'cold-chain' transportation.
We have previously described the retention of TTCF protein structure via ensilication at primary and tertiary level, including heat treated material, using biochemical methodspresent study, we looked at two opposite experimental resolutions. Time resolved (in situ)
SAXS was employed to assess tailor fitting of TTCF in silica. This is a powerful tool that can assess morphology of proteins and particles formed at nanometre scale over time. It provides the average shape and size of (in situ) particle growth using the radius of gyration (Rg) and allows for fitting of mathematical models to elucidate protein-silica particle formation 14,17 .
This could observe and possibly confirm tailored silica coating of TTCF at molecular level. On the other side of the spectrum, in vivo immunisation experiments could confirm feasibility of the end stage application for our methodology creating an opportunity to solve real-world challenges.
Initial assessment of the protein scattering data confirmed a monodisperse solution of native TTCF (Supplementary S1, S2). Calculated parameters elucidate TTCF to be a prolate ellipsoid.
The two independent SAXS experiments performed were intended to provide resolution of the onset and longer evolution of TTCF ensilication. 2, A) . Here, the ensilication process was monitored after ex situ initiation of TTCF ensilication. After measurement was started, the amorphous peak at q-range of 0.03≤q≤0.08 (Å -1 ) (figure 1 and 2, B) was identified in both data sets. Additionally, the rapid increase in high-q signal is present here as well. Observed is the extension of this slope from 0.03≤q≤0.1 (Å -1 ) and indicated mass fractal growth of silica gel around TTCF ensilicated silica particles forming larger aggregates.
There are visible differences in scattering between agitated and non-agitated sample that suggested this reaction to be diffusion controlled ( figure S3 ). Fitting done on both data sets (figure 1&2, C) using various models indicate three stages during ensilication (figure 3).
Stage I: Formation and growth of low q particle radii initiated at the onset of ensilication (figure 1 A, until ~40 sec). Here, ensilication is observed via the increase in ellipsoidal radii (polar, equatorial) over time, indicating silica forming around the protein.
Stage II: Broad amorphous peak formation due to aggregation of silica.
Stage III: Fractal growth of silica particles associated with aggregation which relates to increase in fractal dimension and cut-off length (figure 1, C). This is confirmed by the mass fractal dimension (Df ) during the longer evolution (figure 2, C) which provides an increase to The results confirmed the protective capacity of ensilication to maintain normal protein/epitope conformation at ambient temperature, as well as when the ensilicated material was heated at 80 °C for 2 hours. The ensilicated material used during this study was stored in powdered form for 1 month at room temperature and then transported using commercially available means 
